Digital Health
Dr Mike Trenell
CEO and co-founder of DAISER
Mike is one of the UKs leading digital health entrepreneurs with a rich background in academia and clinical research. He has published >140 peer reviewed papers, including The Lancet and Nature Medicine, and built 2 x national digital technology platforms.
A Clinical Scientist by training, Mike works widely across the life science sector, chairing / mentoring a number of national and global programmes in AI, digital health and regulation.
He works in the intersection between technology, policy, and health - using the latest tools to improve health and care outcomes.
Today, he is the Co-Founder and CEO of Daiser, a next generation digital health company dedicated to enabling the digital transformation of health and is an Honorary Professor of Digital Medicine in the UK and Denmark.
Speak to Mike about building digital health services, commercialisation, AI, lifestyle medicine, metabolism, and entrepreneurship (also coffee, rugby, and snowboarding).
Dr Steve Gardner
CEO and co-founder, PrecisionLife
Steve is a serial technology entrepreneur with over 25 years’ experience developing and commercializing ground-breaking data science and informatics in the healthcare, life sciences and agri-food sectors. Never afraid to innovate, Steve has an established track record in building world-class companies, teams and products working at senior levels in the UK, EU and US for Fortune 500 and start-up companies. He is a former Global Director of Research Informatics for Astra A/B and has consulted with drug discovery and safety teams in over 20 biopharma companies. Steve has held CxO positions and led teams in several international businesses, supplying innovative computational biology, chemistry and semantic data integration tools. He was involved in Oxford Molecular’s IPO and the acquisition and integration of 11 companies. Steve is Chair of the UK BioIndustry Association’s Data, AI and Genomics Advisory Committee, Co-Chair of the Metrodora Foundation’s Scientific Advisory Board, an Editorial Board member for AI in the Life Sciences and was on the Steering Committee of the UKCRC Tissue Directory & Coordination Centre. He advises a range of disease charities, national biobanks and research institutes on precision medicine strategy.
Dr Veronique Bouchet
Chief Medical Officer, PrecsionLife
Véronique is a medical expert and strategic thinker with over 30 years’ experience in the pharmaceutical, biotech anddigital health sectors. She is a former Director of Corporate Strategy and Head of Venture Strategy at AstraZeneca, where she was responsible for global corporate venturing activities, including the creation and $40M financing of the company’s first spinout, Albireo Pharma. She has also held posts in clinical research, licensing, M&A, venture capital and the NHS. This varied experience has given her an in-depth understanding of what is required to translate cutting edge science into commercial reality. Véronique is a non-executive director of International Biotechnology Trust plc. and of the Stevenage Bioscience Catalyst. She is a member of the Scientific Committee of Breast Cancer Now, and of the Council and Finance and Investment Committee of Queen Mary University London (QMUL). She sits on the advisory board of QMUL School of Business and Management and the QMUL Life Sciences in Whitechapel initiative.
Dr Bobby Kaura
Seed Investment, EMEA Outreach & International Development, Illumina Accelerator
Bobby helped co-launch the Cambridge Accelerator, a genomics and VC backable company creation engine. Previously, he was responsible for heading commercial market and business development for Illumina EMEA with a focus on how genomics can enable precision health through the application of next-generation sequencing technologies. He advocates for building ecosystems that support better population and patient outcomes with partners involved in driving forward UK life sciences. Before joining Illumina, he worked in the NHS to deliver sustainable transformation programs and spent several years working in the pharma industry across early research & development, strategic projects (executive) office and leading the UK value-based medicine and pricing innovation stream.
He is a member of the advisory board at Praesens Foundation (set-up to provide access to health programs, to communities in hard-to-reach regions and resource-limited settings), Mentor at Cambridge Judge Business School, NHS Innovation Accelerator and NIHR. In addition, he advises health, tech and blockchain startups.
Bobby read his B.Sc in Biology, with a focus on neuroscience and genomics, and an M.Sc in IT from the Queen Mary University of London.
Bobby Kaura can advise on:
- Strategy and Execution
- Market and Business Development
- Leadership and Mentoring
- Pharma and Diagnostics (personalised healthcare)
- Precision health and (gen)omics and application of next generation sequencing
Please contact the Translational Research Office if you would like to book an appointment with an expert.